

Supplementary Table 5. Incidence rate of the newly diagnosed myocarditis after vaccination according to age and gender

Gender	Age	Vaccination	Total	2 wk				1 mo				3 mo			
				Events	IR*	95% CI	p	Events	IR*	95% CI	p	Events	IR*	95% CI	p
Male	20–24	No	11,509	1	0.87	0.00–2.57	0.999	1	0.87	0.00–2.57	0.487	3	2.61	0.00–5.56	0.999
		Yes	53,070	9	1.70	0.59–2.80		12	2.26	0.98–3.54		15	2.83	1.40–4.26	
	25–29	No	18,808	0	0.00	0.00–0.00	0.557	0	0.00	0.00–0.00	0.186	2	1.06	0.00–2.54	0.734
		Yes	41,197	3	0.73	0.00–1.55		6	1.46	0.29–2.62		8	1.94	0.60–3.29	
	30–34	No	20,506	0	0.00	0.00–0.00	0.025	0	0.00	0.00–0.00	0.013	0	0.00	0.00–0.00	0.007
		Yes	27,715	8	2.89	0.89–4.89		9	3.25	1.13–5.37		10	3.61	1.37–5.84	
	35–39	No	19,335	0	0.00	0.00–0.00	0.088	0	0.00	0.00–0.00	0.047	1	0.52	0.00–1.53	0.159
		Yes	29,629	6	2.03	0.40–3.65		7	2.36	0.61–4.11		7	2.36	0.61–4.11	
	40–44	No	18,591	0	0.00	0.00–0.00	0.331	0	0.00	0.00–0.00	0.067	0	0.00	0.00–0.00	0.041
		Yes	45,308	5	1.10	0.14–2.07		9	1.99	0.69–3.28		11	2.43	0.99–3.86	
	45–49	No	15,604	0	0.00	0.00–0.00	0.580	0	0.00	0.00–0.00	0.580	0	0.00	0.00–0.00	0.580
		Yes	52,911	4	0.76	0.02–1.50		4	0.76	0.02–1.50		4	0.76	0.02–1.50	
	50–59	No	23,821	0	0.00	0.00–0.00	0.999	0	0.00	0.00–0.00	0.617	1	0.42	0.00–1.24	0.999
		Yes	242,344	7	0.29	0.07–0.50		12	0.50	0.22–0.78		13	0.54	0.24–0.83	
	60–+69	No	14,786	0	0.00	0.00–0.00	0.999	0	0.00	0.00–0.00	0.999	0	0.00	0.00–0.00	0.999
		Yes	240,164	1	0.04	0.00–0.12		2	0.08	0.00–0.20		5	0.21	0.03–0.39	
	70–79	No	6,221	0	0.00	0.00–0.00		0	0.00	0.00–0.00	0.999	0	0.00	0.00–0.00	0.999
		Yes	120,228	0	0.00	0.00–0.00		1	0.08	0.00–0.25		1	0.08	0.00–0.25	
	80–89	No	4,059	0	0.00	0.00–0.00	0.999	0	0.00	0.00–0.00	0.999	0	0.00	0.00–0.00	0.999
		Yes	42,782	1	0.23	0.00–0.69		1	0.23	0.00–0.69		4	0.93	0.02–1.85	
Female	20–24	No	14,465	0	0.00	0.00–0.00	0.347	0	0.00	0.00–0.00	0.347	0	0.00	0.00–0.00	0.365
		Yes	47,812	6	1.25	0.25–2.26		6	1.25	0.25–2.26		7	1.46	0.38–2.55	
	25–29	No	18,986	0	0.00	0.00–0.00	0.349	0	0.00	0.00–0.00	0.223	0	0.00	0.00–0.00	0.087
		Yes	65,700	6	0.91	0.18–1.64		9	1.37	0.47–2.26		13	1.98	0.90–3.05	
	30–34	No	25,180	0	0.00	0.00–0.00	0.182	0	0.00	0.00–0.00	0.182	0	0.00	0.00–0.00	0.105
		Yes	52,582	5	0.95	0.12–1.78		5	0.95	0.12–1.78		7	1.33	0.35–2.32	
	35–39	No	23,464	0	0.00	0.00–0.00	0.557	0	0.00	0.00–0.00	0.319	0	0.00	0.00–0.00	0.108
		Yes	52,527	3	0.57	0.00–1.22		4	0.76	0.02–1.51		7	1.33	0.35–2.32	
	40–44	No	20,750	0	0.00	0.00–0.00	0.578	0	0.00	0.00–0.00	0.124	0	0.00	0.00–0.00	0.076
		Yes	61,846	4	0.65	0.01–1.28		9	1.46	0.50–2.41		10	1.62	0.61–2.62	

Supplementary Table 5. Continued

Gender	Age	Vaccina- tion	Total	2 wk				1 mo				3 mo			
				Events	IR*	95% CI	<i>p</i>	Events	IR*	95% CI	<i>p</i>	Events	IR*	95% CI	<i>p</i>
	45–49	No	17,078	0	0.00	0.00–0.00	0.999	0	0.00	0.00–0.00	0.358	1	0.59	0.00–1.73	0.698
		Yes	68,432	3	0.44	0.00–0.93		7	1.02	0.27–1.78		9	1.32	0.46–2.17	
	50–59	No	24,034	0	0.00	0.00–0.00	0.999	0	0.00	0.00–0.00	0.634	1	0.42	0.00–1.23	0.999
		Yes	273,906	8	0.29	0.09–0.49		16	0.58	0.30–0.87		20	0.73	0.41–1.05	
	60–+69	No	18,560	0	0.00	0.00–0.00	0.999	0	0.00	0.00–0.00	0.999	1	0.54	0.00–1.59	0.363
		Yes	279,119	4	0.14	0.00–0.28		5	0.18	0.02–0.34		6	0.21	0.04–0.39	
	70–79	No	8,806	0	0.00	0.00–0.00		0	0.00	0.00–0.00	0.999	0	0.00	0.00–0.00	0.999
		Yes	150,143	0	0.00	0.00–0.00		2	0.13	0.00–0.32		3	0.20	0.00–0.43	
	80–89	No	10,020	0	0.00	0.00–0.00		0	0.00	0.00–0.00		0	0.00	0.00–0.00	0.999
		Yes	70,469	0	0.00	0.00–0.00		0	0.00	0.00–0.00		2	0.28	0.00–0.68	

IR, incidence rate; CI, confidence interval.

*Per 10,000 persons.